Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody-Drug Conjugate.
Singh S, Serwer L, DuPage A, Elkins K, Chauhan N, Ravn M, Buchanan F, Wang L, Krimm M, Wong K, Sagert J, Tipton K, Moore SJ, Huang Y, Jang A, Ureno E, Miller A, Patrick S, Duvur S, Liu S, Vasiljeva O, Li Y, Henriques T, Badagnani I, Jeffries S, Schleyer S, Leanna R, Krebber C, Viswanathan S, Desnoyers L, Terrett J, Belvin M, Morgan-Lappe S, Kavanaugh WM, Richardson J.
Singh S, et al. Among authors: liu s.
Mol Cancer Ther. 2022 Aug 2;21(8):1326-1336. doi: 10.1158/1535-7163.MCT-21-0193.
Mol Cancer Ther. 2022.
PMID: 35666803
Free PMC article.